Regdanvimab demonstrates strong neutralising activity against Delta variant of COVID-19
Celltrion Group today announced new results from an in vivo efficacy study showing that regdanvimab, CT-P59 has a strong neutralising effect against the rapidly spreading Delta variant, B.1.617.2, first identified in India.
According to the World Health Organization, WHO, the Delta variant has been reported in 96 countries becoming the most common variant.1




















